158 related articles for article (PubMed ID: 28237353)
1. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].
Baudouin A; Fargier E; Cerruti A; Dubromel A; Vantard N; Ranchon F; Schwiertz V; Salles G; Souquet PJ; Thomas L; Bérard F; Nancey S; Freyer G; Trillet-Lenoir V; Rioufol C
Bull Cancer; 2017 Jun; 104(6):538-551. PubMed ID: 28237353
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
[TBL] [Abstract][Full Text] [Related]
4. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
5. [Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement].
Wilkowsky C; Lenain A; Benbekhaled K; Le Gall MJ; Vignot S
Bull Cancer; 2016 Apr; 103(4):353-60. PubMed ID: 27017057
[TBL] [Abstract][Full Text] [Related]
6. [The cost of chemotherapy].
Lévy C; Bonastre J
Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
[TBL] [Abstract][Full Text] [Related]
7. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
8. [Generic drugs in the medical-economic context of drug prescriptions].
Bouvenot G; Villani P; Bouvenot J
Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
10. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
11. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
12. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
13. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
14. Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts.
Benjamin L; Buthion V; Vidal-Trécan G; Briot P
BMC Health Serv Res; 2014 Jun; 14():274. PubMed ID: 24950778
[TBL] [Abstract][Full Text] [Related]
15. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Mora C; González A; Díaz J; Quintana G
Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
[TBL] [Abstract][Full Text] [Related]
16. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
[TBL] [Abstract][Full Text] [Related]
17. [Anticancer drugs: Which prices for therapeutic innovations?].
Gonçalves A; Maraninchi D; Marino P
Bull Cancer; 2016 Apr; 103(4):361-7. PubMed ID: 27045535
[TBL] [Abstract][Full Text] [Related]
18. The impact of pricing strategy on the costs of oral anti-cancer drugs.
Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
[TBL] [Abstract][Full Text] [Related]
19. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
Claus BO; Robays H; Decruyenaere J; Annemans L
J Eval Clin Pract; 2014 Dec; 20(6):1172-9. PubMed ID: 25470782
[TBL] [Abstract][Full Text] [Related]
20. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
